Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy
Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman · 2026
Read Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy by Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13525373.txt.
Description
Five authors report a study dated two thousand twenty-six on a form of inflammatory arthritis of the spine. The condition is axial spondyloarthritis. Some patients do not respond to a first biologic drug, secukinumab, and doctors must pick the next drug with little guidance on who will benefit.
The team re-read immune data from eighteen patients who had not responded. Eight were switched to a different class of biologic, and ten had their dose raised. Falls in two sets of helper T cells during the first drug marked the patients who later did well. Disease activity was checked at week twenty-four to judge the response.
Catalog record
| CREATOR | Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |